Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...

Shares of Eli Lilly and Co. LLY tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of ...

(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.

Highlights,Eli Lilly reported third-quarter profits that fell short of Wall Street estimates, primarily due to higher ...

Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.